Evidence map›Paper›PMID 37460928›Full record

ArticleJournal of ovarian research2023

Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.

A W Adamson, Y C Ding, L Steele, L A Leong, R Morgan, M T Wakabayashi, E S Han, T H Dellinger, P S Lin, A A Hakim and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of ovarian research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

A W AdamsonDepartment of Population Sciences, Beckman Research Institute of City of Hope, CA, Duarte, USA.
Y C DingDepartment of Population Sciences, Beckman Research Institute of City of Hope, CA, Duarte, USA.
L SteeleDepartment of Population Sciences, Beckman Research Institute of City of Hope, CA, Duarte, USA.
L A LeongFormerly, Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
R MorganFormerly, Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
M T WakabayashiCurrently at Regeneron Pharmaceuticals Inc, Formerly City of Hope National Medical Center, Duarte, CA, USA.
E S HanDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
T H DellingerDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
P S LinFormerly, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
A A HakimDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
S WilczynskiDepartment of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
C D WardenIntegrative Genomics Core, Beckman Research Institute of City of Hope, Duarte, CA, USA.
S TaoIntegrative Genomics Core, Beckman Research Institute of City of Hope, Duarte, CA, USA.
V BedellCytogenetics Core, City of Hope National Medical Center, Duarte, CA, USA.
M C CristeaFormerly, Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
S L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, CA, Duarte, USA. sneuhausen@coh.org.
City Of Hope National Medical Center · USBeckman Research InstituteCity of Hope · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

backgroundHigh-grade serous ovarian cancers (HGSCs) display a high degree of complex genetic alterations. In this study, we identified germline and somatic genetic alterations in HGSC and their association with relapse-free and overall survival. Using a targeted capture of 557 genes involved in DNA damage response and PI3K/AKT/mTOR pathways, we conducted next-generation sequencing of DNA from matched blood and tumor tissue from 71 HGSC participants. In addition, we performed the OncoScan assay on tumor DNA from 61 participants to examine somatic copy number alterations (SCNA).

resultsApproximately one-third of tumors had loss-of-function (LOF) germline (18/71, 25.4%) or somatic (7/71, 9.9%) variants in the DNA homologous recombination repair pathway genes BRCA1, BRCA2, CHEK2, MRE11A, BLM, and PALB2. LOF germline variants also were identified in other Fanconi anemia genes and in MAPK and PI3K/AKT/mTOR pathway genes. Most tumors harbored somatic TP53 variants (65/71, 91.5%). Using the OncoScan assay on tumor DNA from 61 participants, we identified focal homozygous deletions in BRCA1, BRCA2, MAP2K4, PTEN, RB1, SLX4, STK11, CREBBP, and NF1. In total, 38% (27/71) of HGSC patients harbored pathogenic variants in DNA homologous recombination repair genes. For patients with multiple tissues from the primary debulking or from multiple surgeries, the somatic mutations were maintained with few newly acquired point mutations suggesting that tumor evolution was not through somatic mutations. There was a significant association of LOF variants in homologous recombination repair pathway genes and high-amplitude somatic copy number alterations. Using GISTIC analysis, we identified NOTCH3, ZNF536, and PIK3R2 in these regions that were significantly associated with an increase in cancer recurrence and a reduction in overall survival.

conclusionsFrom 71 patients with HGCS, we performed targeted germline and tumor sequencing and provided a comprehensive analysis of these 557 genes. We identified germline and somatic genetic alterations including somatic copy number alterations and analyzed their associations with relapse-free and overall survival. This single-site long-term follow-up study provides additional information on genetic alterations related to occurrence and outcome of HGSC. Our findings suggest that targeted treatments based on both variant and SCNA profile potentially could improve relapse-free and overall survival.

Indexed as

Ovarian NeoplasmsFemaleFollow-Up StudiesGenomicsHumansNeoplasm Recurrence, LocalPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesGermline mutationsHigh-grade serous ovarian cancerHomologous recombination repairSomatic copy number alterationsSomatic mutations

Identifiers

PMID37460928
PMCPMC10351177
OpenAlexW4384559291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.